As Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Biologics Limited, noted regarding demand and growth potential for GLP-1 therapies, There will be a requirement for significantly higher volumes and Biocons fermentation capability will give us a significant advantage. India leads with a CAGR of 8.4%, driven by a large diabetic population and increasing demand for effective treatments
Our recommendations prioritize safety, formulation, and accessibility to help you choose a supplement that fits your skin goals and daily routine
Comprehensive analysis of Acylcarnitine species in db/db mouse using a novel method of high-resolution parallel reaction monitoring reveals widespread metabolic dysfunction induced by diabetes
Rushing the reconstitution process can damage the peptide or create uneven dissolution that affects dosing accuracy
Kiessling, M., Herchenhan, E